168 related articles for article (PubMed ID: 31389706)
1. Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy.
Wang Q; Luo M; Wei N; Chang A; Luo KQ
Mol Pharm; 2019 Sep; 16(9):3873-3886. PubMed ID: 31389706
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the bioavailability of a novel anticancer compound (acetyltanshinone IIA) by encapsulation within mPEG-PLGA nanoparticles: a study of formulation optimization, toxicity, and pharmacokinetics.
Wang Q; Wei N; Liu X; Chang A; Luo KQ
Oncotarget; 2017 Feb; 8(7):12013-12030. PubMed ID: 28061455
[TBL] [Abstract][Full Text] [Related]
3. The potential utility of acetyltanshinone IIA in the treatment of HER2-overexpressed breast cancer: Induction of cancer cell death by targeting apoptotic and metabolic signaling pathways.
Guerram M; Jiang ZZ; Yousef BA; Hamdi AM; Hassan HM; Yuan ZQ; Luo HW; Zhu X; Zhang LY
Oncotarget; 2015 Sep; 6(26):21865-77. PubMed ID: 26068969
[TBL] [Abstract][Full Text] [Related]
4. A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the intrinsic apoptotic pathway.
Tian HL; Yu T; Xu NN; Feng C; Zhou LY; Luo HW; Chang DC; Le XF; Luo KQ
Cancer Lett; 2010 Nov; 297(1):18-30. PubMed ID: 20494511
[TBL] [Abstract][Full Text] [Related]
5. Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells.
Huang B; Yip WK; Wei N; Luo KQ
Cancer Lett; 2020 Oct; 490():1-11. PubMed ID: 32585412
[TBL] [Abstract][Full Text] [Related]
6. A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor.
Yu T; Zhou Z; Mu Y; de Lima Lopes G; Luo KQ
Cancer Lett; 2014 Apr; 346(1):94-103. PubMed ID: 24374015
[TBL] [Abstract][Full Text] [Related]
7. Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.
Shahin M; Soudy R; Aliabadi HM; Kneteman N; Kaur K; Lavasanifar A
Biomaterials; 2013 May; 34(16):4089-4097. PubMed ID: 23465829
[TBL] [Abstract][Full Text] [Related]
8. Preparation, characterization, and assessment of the antiglioma effects of liposomal celastrol.
Huang Y; Zhou D; Hang T; Wu Z; Liu J; Xu Q; Xie X; Zuo J; Wang Z; Zhou Y
Anticancer Drugs; 2012 Jun; 23(5):515-24. PubMed ID: 22343423
[TBL] [Abstract][Full Text] [Related]
9. Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy.
Liu J; Lee H; Huesca M; Young A; Allen C
Cancer Chemother Pharmacol; 2006 Sep; 58(3):306-18. PubMed ID: 16333677
[TBL] [Abstract][Full Text] [Related]
10. Development of Liposomal Formulation for Delivering Anticancer Drug to Breast Cancer Stem-Cell-Like Cells and its Pharmacokinetics in an Animal Model.
Ahmad A; Mondal SK; Mukhopadhyay D; Banerjee R; Alkharfy KM
Mol Pharm; 2016 Mar; 13(3):1081-8. PubMed ID: 26832839
[TBL] [Abstract][Full Text] [Related]
11. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
[TBL] [Abstract][Full Text] [Related]
12. Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.
Cai XJ; Fei WD; Xu YY; Xu H; Yang GY; Cao JW; Ni JJ; Wang Z
Drug Deliv Transl Res; 2020 Feb; 10(1):93-107. PubMed ID: 31418132
[TBL] [Abstract][Full Text] [Related]
13. Liposomal Formulation of a Melphalan Lipophilic Prodrug: Studies of Acute Toxicity, Tolerability, and Antitumor Efficacy.
Tretiakova D; Svirshchevskaya E; Onishchenko N; Alekseeva A; Boldyrev I; Kamyshinsky R; Natykan A; Lokhmotov A; Arantseva D; Shobolov D; Vodovozova E
Curr Drug Deliv; 2020; 17(4):312-323. PubMed ID: 32056524
[TBL] [Abstract][Full Text] [Related]
14. Liposomal borrelidin for treatment of metastatic breast cancer.
Jeong M; Kim H; Kim S; Park JH
Drug Deliv Transl Res; 2018 Oct; 8(5):1380-1388. PubMed ID: 30027371
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
16. A near-infrared two-photon-sensitive peptide-mediated liposomal delivery system.
Yang Y; Yang Y; Xie X; Cai X; Wang Z; Gong W; Zhang H; Li Y; Mei X
Colloids Surf B Biointerfaces; 2015 Apr; 128():427-438. PubMed ID: 25766920
[TBL] [Abstract][Full Text] [Related]
17. Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model.
Eldin NE; Abu Lila AS; Kawazoe K; Elnahas HM; Mahdy MA; Ishida T
Eur J Pharm Sci; 2016 Jan; 81():60-6. PubMed ID: 26415830
[TBL] [Abstract][Full Text] [Related]
18. PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.
Zhang L; Cao DY; Wang J; Xiang B; Dun JN; Fang Y; Xue GQ
Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3347-61. PubMed ID: 24379067
[TBL] [Abstract][Full Text] [Related]
19. Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer.
Bai F; Yin Y; Chen T; Chen J; Ge M; Lu Y; Xie F; Zhang J; Wu K; Liu Y
Int J Nanomedicine; 2018; 13():1327-1339. PubMed ID: 29563790
[TBL] [Abstract][Full Text] [Related]
20. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells.
Guo J; Zhou J; Ying X; Men Y; Li RJ; Zhang Y; Du J; Tian W; Yao HJ; Wang XX; Ju RJ; Lu WL
J Pharm Pharm Sci; 2010; 13(2):136-51. PubMed ID: 20816001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
